GlaxoSmithKline (GSK – Egypt) (EGX:BIOC) announced exceptional dividends of EGP 250.543 million, or EGP 3 per share, for the period ended in April 2022, according to a filing to the Egyptian Exchange (EGX) on Wednesday.

    It is worth noting that the company’s standalone net profit soared to EGP 929.74 million in January to September from EGP 89.839 million in the same period a year earlier.

     

    GSK Egypt, a member of the British pharmaceutical company Glaxo Group, is an Egypt-based company engaged in the manufacturing, packaging, marketing, selling, and distribution of pharmaceutical products.

     

    MARKET STATUS: CLOSED

    🇪🇬 Egyptian Pound



    african indices

    BRVM-CI212.47+0.44%23/02
    BSE DCI9,001.84-23/02
    DSE ASI1,765.96-0.15%23/02
    EGX 3029,309.73+0.06%22/02
    GSE-CI3,185.18+0.02%23/02
    JSE ASI74,213.39+0.14%23/02
    LuSE ASI11,693.44-23/02
    MASI13,083.17+0.74%23/02
    MSE ASI114,374.77-23/02
    NGX ASI102,088.30+0.84%23/02
    NSE ASI92.83+0.17%23/02
    NSX OI1,551.37+0.01%23/02
    RSE ASI144.47-23/02
    SEM ASI1,891.78-0.02%23/02
    TUNINDEX8,524.62+0.33%23/02
    USE ASI913.97+0.52%23/02
    ZSE ASI496,276.62-1.17%23/02